Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK - Pub
4 hours ago
- #tirzepatide
- #type 2 diabetes
- #cost analysis
- Tirzepatide is a treatment for type 2 diabetes improving glycemic control and weight loss with low hypoglycemia risk.
- A cost analysis compared tirzepatide (5, 10, 15 mg) vs. semaglutide 1 mg in the UK for achieving composite endpoints.
- Composite endpoints included HbA1c control (≤6.5%, <7.0%), weight loss (≥5%, ≥10%, ≥15%), and no hypoglycemia.
- Tirzepatide showed lower pharmacy costs per patient achieving targets than semaglutide for most endpoints.
- Cost differences were greater for stricter targets (e.g., HbA1c ≤6.5% + weight loss ≥15% + no hypoglycemia).
- Semaglutide 1 mg had lower costs only for HbA1c <7.0% + weight loss ≥5% + no hypoglycemia.
- Tirzepatide is more cost-effective for achieving treatment targets in type 2 diabetes patients in the UK.